Waters Corp
XMUN:WAZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Waters Corp
XMUN:WAZ
|
US |
|
A
|
Avnet Inc
F:VNI
|
US |
|
C
|
Credit Suisse Group AG
LSE:0QP5
|
CH |
|
ACS Actividades de Construccion y Servicios SA
F:OCI
|
ES |
|
S
|
Star Bulk Carriers Corp
SWB:4FAP
|
GR |
|
S
|
Societe Generale SA
XBER:SGE
|
FR |
|
F
|
Fortescue Metals Group Ltd
XBER:FVJ
|
AU |
|
S
|
Spotify Technology SA
SWB:639
|
LU |
|
V
|
Valneva SE
LSE:0OB3
|
FR |
|
S
|
Simon Property Group Inc
SWB:SQI
|
US |
|
F
|
Fomento Economico Mexicano SAB de CV
SWB:FOMA
|
MX |
|
Paramount Global
NASDAQ:PSKY
|
US |
|
Orell Fuessli AG
F:OFH
|
CH |
|
G
|
General Electric Co
BMV:GE
|
US |
|
T
|
Toll Brothers Inc
XBER:TLK
|
US |
|
E
|
Eli Lilly and Co
F:LLY
|
US |
|
Vodafone Group PLC
LSE:VOD
|
UK |
|
C
|
Crown Castle International Corp
F:8CW
|
US |
|
Novus Holdings Ltd
F:N09
|
ZA |
|
Ajinomoto Co Inc
TSE:2802
|
JP |
|
E ON SE
MIL:1EOAN
|
DE |
|
N
|
NTT Data Corp
XBER:NT5
|
JP |
|
Global Education Communities Corp
F:O3V
|
CA |
Waters Corp
Waters Corporation makes scientific instruments and lab software that help customers identify, measure, and separate chemicals in complex samples. Its main products are liquid chromatography systems, mass spectrometry systems, and the columns, spare parts, and software that go with them. These tools are used when labs need precise answers about what is in a drug, food, chemical, or biological sample. Its main customers are pharmaceutical and biotech companies, contract research labs, universities, government labs, and some industrial testing labs. Waters sells instruments upfront and then earns repeat business from consumable products like columns and from service, maintenance, and software. That mix gives the company both equipment sales and a steadier follow-on revenue stream tied to how much customers use the instruments. Waters sits in an important spot in the scientific testing chain: it helps labs move from raw samples to reliable data they can use for research, quality control, and regulatory work. It is not selling the drug or chemical itself; it sells the measurement tools that prove what that product contains and whether it meets standards. That makes the business closely linked to long-term spending on drug development, lab testing, and regulated manufacturing.
Waters Corporation makes scientific instruments and lab software that help customers identify, measure, and separate chemicals in complex samples. Its main products are liquid chromatography systems, mass spectrometry systems, and the columns, spare parts, and software that go with them. These tools are used when labs need precise answers about what is in a drug, food, chemical, or biological sample.
Its main customers are pharmaceutical and biotech companies, contract research labs, universities, government labs, and some industrial testing labs. Waters sells instruments upfront and then earns repeat business from consumable products like columns and from service, maintenance, and software. That mix gives the company both equipment sales and a steadier follow-on revenue stream tied to how much customers use the instruments.
Waters sits in an important spot in the scientific testing chain: it helps labs move from raw samples to reliable data they can use for research, quality control, and regulatory work. It is not selling the drug or chemical itself; it sells the measurement tools that prove what that product contains and whether it meets standards. That makes the business closely linked to long-term spending on drug development, lab testing, and regulated manufacturing.
Beat and raise: Waters reported first-quarter revenue of $1.267 billion and adjusted EPS of $2.70, both well above guidance, and raised full-year organic growth and EPS outlooks.
Legacy strength: The core business delivered 11% constant-currency organic growth, led by strong demand in pharma, academic and government, chemistry, and service.
Acquisition momentum: The newly acquired Biosciences and Diagnostic Solutions businesses both came in ahead of expectations, helped by faster commercial execution, pricing actions, and early cross-selling.
Outlook improving: Management raised full-year organic constant-currency revenue growth to 6.5% to 8% and adjusted EPS to $14.40 to $14.60, while flagging stronger visibility into the second half.
Synergy upside: The company said it is on track for $55 million of cost synergies and $50 million of revenue synergies in 2026, with some benefits expected to begin flowing through starting in the third quarter.
